Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.

Abstract:

OBJECTIVE:To evaluate safety, tolerability, and antitumor activity of pembrolizumab monotherapy in patients with programmed death ligand 1 (PD-L1)-expressing advanced ovarian cancer enrolled in the multicohort, phase Ib KEYNOTE-028 trial. METHODS:Key inclusion criteria were age ≥18 years; advanced ovarian epithelial, fallopian tube, or primary peritoneal carcinoma; failure of previous therapy; and tumor PD-L1 positivity. Patients received pembrolizumab (10 mg/kg every 2 weeks) for ≤24 months or until disease progression/intolerable toxicity. Tumor response was assessed per RECIST v1.1 (investigator review). Adverse events (AEs) were graded using CTCAE version 4.0. Primary end point was confirmed objective response rate (ORR) per RECIST v1.1 (investigator review); data cutoff date was February 20, 2017. RESULTS:Twenty-six patients (median age, 57.5 years) with PD-L1-positive advanced metastatic ovarian cancer received pembrolizumab; 38.5% had metastatic disease, and 73.1% previously received ≥3 lines of therapy. Treatment-related AEs (TRAEs) occurred in 19 (73.1%) patients, most commonly arthralgia (19.2%), nausea (15.4%), and pruritus (15.4%). One grade 3 TRAE (increased plasma transaminase level) occurred. No deaths and no treatment discontinuations due to TRAEs occurred. After a median follow-up duration of 15.4 months, ORR was 11.5% (1 complete response, 2 partial responses); 7 patients (26.9%) achieved stable disease. Median progression-free and overall survival were 1.9 (95% CI, 1.8-3.5) and 13.8 (95% CI, 6.7-18.8) months, respectively. CONCLUSION:Pembrolizumab conferred durable antitumor activity with manageable safety and toxicity in patients with advanced PD-L1-positive ovarian cancer and is under further investigation in an ongoing phase II trial, KEYNOTE-100.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Varga A,Piha-Paul S,Ott PA,Mehnert JM,Berton-Rigaud D,Morosky A,Yang P,Ruman J,Matei D

doi

10.1016/j.ygyno.2018.11.017

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

243-250

issue

2

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(18)31418-5

journal_volume

152

pub_type

杂志文章,多中心研究
  • Screening practices and invasive cervical cancer risk in different age strata.

    abstract::Relative and population attributable risks for invasive cervical cancer in different age strata relative to screening practices have been estimated using data from a case-control study conducted since 1981 in the greater Milan area, northern Italy. A total of 548 women under 75 years of age with a histologically confi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90015-d

    authors: Parazzini F,Negri E,La Vecchia C,Bocciolone L

    更新日期:1990-07-01 00:00:00

  • Adjunctive hysterectomy following radiation therapy for bulky carcinoma of the uterine cervix: prognostic implications of tumor persistence.

    abstract::Twenty-five patients underwent adjunctive extrafascial hysterectomy 14-60 days following completion of external and intracavitary irradiation for bulky carcinoma of the uterine cervix. Review of the operative histopathology and correlation with subsequent patient outcomes suggests that morphologically persistent cance...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(87)90217-4

    authors: Russell AH,Burt AR,Ek M,Russell KJ,Cain JM,Greer BE,Tamimi HK,Figge DC

    更新日期:1987-10-01 00:00:00

  • Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies.

    abstract:OBJECTIVE:To compare outcomes of patients undergoing continent or incontinent urinary diversion after pelvic exenteration for gynecologic malignancies. METHODS:Data on patients who underwent pelvic exenteration for gynecologic malignancies at The University of Texas MD Anderson Cancer Center between January 1993 and D...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.02.024

    authors: Urh A,Soliman PT,Schmeler KM,Westin S,Frumovitz M,Nick AM,Fellman B,Urbauer DL,Ramirez PT

    更新日期:2013-06-01 00:00:00

  • Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

    abstract:OBJECTIVE:This study investigated the relationship between 13 proteins involved in DNA damage and the outcomes of patients with recurrent ovarian cancer (ROC). PATIENTS AND METHODS:Immunohistochemistry staining was performed in 114 diagnostic samples from patients with serous ROC who participated in the OVA-301 study,...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.10.032

    authors: Monk BJ,Kaye SB,Poveda A,Herzog TJ,Aracil M,Nieto A,Badri N,Parekh TV,Tanović A,Galmarini CM

    更新日期:2014-01-01 00:00:00

  • Cytoreduction of diaphragmatic metastasis from ovarian cancer with involvement of the liver using a ventral liver mobilization technique.

    abstract:OBJECTIVE:Upper abdominal spreading of advanced-stage ovarian cancer often involves the diaphragm. In addition, bulky diaphragmatic tumors occasionally infiltrate the liver. Here, we describe our early experiences with a ventral liver mobilization technique to remove diaphragmatic tumors with liver involvement. METHOD...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2016.01.017

    authors: Kato K,Katsuda T,Takeshima N

    更新日期:2016-03-01 00:00:00

  • Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.

    abstract:OBJECTIVE:The first-line chemotherapy for ovarian cancer is based on a combination of platinum and taxane. To date, no reliable predictive biomarker has been recognized that is capable of identifying patients with pre-existing resistance to these agents. Here, we have established an integrated database and identified t...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.01.006

    authors: Fekete JT,Ősz Á,Pete I,Nagy GR,Vereczkey I,Győrffy B

    更新日期:2020-03-01 00:00:00

  • The inherent cellular radiosensitivity of epithelial ovarian carcinoma.

    abstract::Ovarian carcinomas of similar histology have variable responses to radiation therapy. It has been suggested that inherent cellular resistance to radiation may in part underlie radiotherapy failure. To determine in vitro radiobiological parameters of papillary serous adenocarcinoma of the ovary, we investigated the cel...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90063-2

    authors: Rotmensch J,Schwartz JL,Atcher RW,Grdina DJ,Toohill M,Weichselbaum RW

    更新日期:1989-12-01 00:00:00

  • Robotic versus open radical hysterectomy: a comparative study at a single institution.

    abstract:OBJECTIVE:To compare the short-term surgical outcome of patients undergoing robotic radical hysterectomy (RRH) versus open radical hysterectomy (ORH) for the treatment of early stage cervical cancer. METHODS:IRB approval was obtained for a retrospective chart review of all radical hysterectomies (RHs) for Stage I and ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.08.016

    authors: Ko EM,Muto MG,Berkowitz RS,Feltmate CM

    更新日期:2008-12-01 00:00:00

  • CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.

    abstract::Nineteen patients with stage III or IV epithelial ovarian cancer treated on a prospective randomized protocol with either adriamycin and cis-diamminedichloroplatinum or tamoxifen, adriamycin, and cis-diamminedichloroplatinum received a modified "CHAP II" regimen at the time of clinical progression of disease or the fi...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0090-8258(86)90085-5

    authors: Schwartz PE,Keating G,Kohorn EI,Chambers JT

    更新日期:1986-11-01 00:00:00

  • Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma.

    abstract::Fifty consecutive patients with documented advanced or recurrent endometrial carcinoma from 1978 through 1985 were prospectively treated with melphalan, 5-fluorouracil, medroxyprogesterone acetate (MFP) as first-line chemotherapy. From 1987 through 1993, 50 consecutive patients with documented advanced or recurrent en...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.1995.0015

    authors: Cornelison TL,Baker TR,Piver MS,Driscoll DL

    更新日期:1995-11-01 00:00:00

  • Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

    abstract:BACKGROUND:Several cytokines have been associated with immune regulation and prognosis in ovarian cancer. CD4+CD25+ Tregs and CD3+CD56+ NK-like T cells are involved in the immune response against the tumor. We have investigated the association of cytokines in the ascites from patients with ovarian cancer with these pop...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.10.018

    authors: Bamias A,Koutsoukou V,Terpos E,Tsiatas ML,Liakos C,Tsitsilonis O,Rodolakis A,Voulgaris Z,Vlahos G,Papageorgiou T,Papatheodoridis G,Archimandritis A,Antsaklis A,Dimopoulos MA

    更新日期:2008-02-01 00:00:00

  • Gynecologic melanomas: A clinicopathologic and molecular analysis.

    abstract:OBJECTIVE:Melanoma originating from gynecologic sites (MOGS), including the vulva, vagina, and cervix, is a rare and aggressive form of melanoma with poor long-term clinical outcome. The clinicopathologic features of vulvar and non-vulvar tumors remain relatively understudied, and in contrast to cutaneous melanomas at ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.08.023

    authors: Udager AM,Frisch NK,Hong LJ,Stasenko M,Johnston CM,Liu JR,Chan MP,Harms PW,Fullen DR,Orsini A,Thomas DG,Lowe L,Patel RM

    更新日期:2017-11-01 00:00:00

  • 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.

    abstract::Twenty-nine patients with recurrent advanced stage ovarian cancer were treated with 5-fluorouracil (5-FU) and leucovorin by intravenous bolus on 5 consecutive days, repeated every 3 weeks. Twenty-one of these patients had experienced disease progression while receiving a cisplatin- or carboplatin-based regimen. There ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90226-9

    authors: Reed E,Jacob J,Ozols RF,Young RC,Allegra C

    更新日期:1992-09-01 00:00:00

  • Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

    abstract:OBJECTIVE:BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associat...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.06.012

    authors: Vicus D,Rosen B,Lubinski J,Domchek S,Kauff ND,Lynch HT,Isaacs C,Tung N,Sun P,Narod SA,Hereditary Ovarian Cancer Clinical Study Group.

    更新日期:2009-10-01 00:00:00

  • When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.

    abstract::The COVID-19 pandemic has challenged our ability to provide timely surgical care for our patients. In response, the U.S. Surgeon General, the American College of Srugeons, and other surgical professional societies recommended postponing elective surgical procedures and proceeding cautiously with cancer procedures that...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2020.06.001

    authors: Fader AN,Huh WK,Kesterson J,Pothuri B,Wethington S,Wright JD,Bakkum-Gamez JN,Soliman PT,Sinno AK,Leitao M,Martino MA,Karam A,Rossi E,Brown J,Blank S,Burke W,Goff B,Yamada SD,Uppal S,Dowdy SC

    更新日期:2020-08-01 00:00:00

  • A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer.

    abstract:OBJECTIVES:Limited knowledge exists about the value of tumor size in surgically treated cervical cancer (CX) using a tumor size of 2 cm as cut-off value. METHODS:A total of 366 cases of CX FIGO stage IB who received upfront surgery were evaluated regarding tumor size, the prediction of pelvic lymph node involvement, a...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.04.011

    authors: Horn LC,Bilek K,Fischer U,Einenkel J,Hentschel B

    更新日期:2014-07-01 00:00:00

  • Overexpression of kallikrein 10 in epithelial ovarian carcinomas.

    abstract:OBJECTIVE:We wanted to identify genes up-regulated in ovarian tumors that might serve as early markers for ovarian cancer. One promising focus is the family of genes that encode secreted proteases, which play essential roles in tumor invasion and metastasis. Kallikrein 10 (KLK10) is a member of the kallikrein family of...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(03)00257-9

    authors: Shvartsman HS,Lu KH,Lee J,Lillie J,Deavers MT,Clifford S,Wolf JK,Mills GB,Bast RC Jr,Gershenson DM,Schmandt R

    更新日期:2003-07-01 00:00:00

  • Palliative radiotherapy for recurrent granulosa cell tumor of the ovary: a report of 3 cases with radiological evidence of response.

    abstract:BACKGROUND:The role of radiotherapy for recurrent or residual granulosa cell tumor of the ovary (GCTO) is controversial. One reason for this controversy may be that most published studies on this topic have not utilized sectional imaging to assess response to radiotherapy. We report on three cases of recurrent or resid...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.02.034

    authors: E C,Samant R,Fung MF,Le T,Hopkins L,Senterman M

    更新日期:2006-08-01 00:00:00

  • Prognosis of ovarian cancer developing in the residual ovary.

    abstract::Elective oophorectomy at the time of hysterectomy for benign disease in women during their fifth decade is an important issue for both gynecologist and patient. It has been suggested that cancer developing in the residual ovary has a worse prognosis than the national average (L. McGowan, Obstet. Gynecol. 69, 386, 1987...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(91)90065-d

    authors: Fine BA,Yazigi R,Risser R

    更新日期:1991-11-01 00:00:00

  • Abnormal cervical cytology leading to the diagnosis of gastric cancer.

    abstract::There have been nine cases reported in the English literature in which the finding of malignant cells on cervical/vaginal cytology led to the diagnosis of primary gastric cancer. We report on a patient with gastric carcinoma, metastatic to the cervix, in which the diagnosis was suspected by the finding of signet ring ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/0090-8258(90)90117-4

    authors: McGill F,Adachi A,Karimi N,Wadler S,Kim ES,Greston WM,Kleiner GJ

    更新日期:1990-01-01 00:00:00

  • DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.

    abstract:OBJECTIVE:The present study was undertaken to analyze the impact of epigenetic alterations with a main focus on nuclear area, aneuploidy, hyperploidy, and proliferation in 70 ovarian cancer specimens. METHODS:Morphometric changes and somatic chromosomal ploidy status were assessed by Feulgen spectrophotometry. DNA-hyp...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.12.332

    authors: Zeimet AG,Fiegl H,Goebel G,Kopp F,Allasia C,Reimer D,Steppan I,Mueller-Holzner E,Ehrlich M,Marth C

    更新日期:2011-04-01 00:00:00

  • Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.

    abstract:OBJECTIVE:To examine patterns of patient travel among women with ovarian cancer and to explore the association between travel distance and short and long-term outcomes. METHODS:Women with stage II-IV epithelial ovarian cancer diagnosed from 2004 to 2016 who underwent primary surgery were identified in the National Can...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.05.017

    authors: Knisely A,Huang Y,Melamed A,Tergas AI,St Clair CM,Hou JY,Khoury-Collado F,Ananth CV,Neugut AI,Hershman DL,Wright JD

    更新日期:2020-08-01 00:00:00

  • Introduction of transperitoneal lymphadenectomy in a gynecologic oncology center: analysis of 650 laparoscopic pelvic and/or paraaortic transperitoneal lymphadenectomies.

    abstract:OBJECTIVE:Lymphadenectomy is an integral part of staging and treatment of gynecologic malignancies. We evaluated the feasibility and oncologic value of laparoscopic transperitoneal pelvic and paraaortic lymphadenectomy in correlation to complication rate and body mass index. METHODS:Between August 1994 and September 2...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.07.025

    authors: Köhler C,Klemm P,Schau A,Possover M,Krause N,Tozzi R,Schneider A

    更新日期:2004-10-01 00:00:00

  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

    abstract:OBJECTIVES:The efficacy and safety of bevacizumab and docetaxel were evaluated in women who developed recurrent epithelial ovarian, fallopian, or peritoneal cancer within 12 months of platinum-based therapy. METHODS:Patients received docetaxel (40 mg/m(2)) on days 1 and 8 and bevacizumab (15 mg/kg) on day 1 of a 21-da...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.04.049

    authors: Wenham RM,Lapolla J,Lin HY,Apte SM,Lancaster JM,Judson PL,Gonzalez-Bosquet J,Herschberger A,Havrilesky LJ,Secord AA

    更新日期:2013-07-01 00:00:00

  • Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.

    abstract:OBJECTIVE:Collagen gel constitutes a valuable tool for the study of cell-matrix interactions; however, it is sometimes difficult to use the gel, in which tumor and stromal cells are cocultured, for immunohistochemistry, because it is easily broken during the process of fixation and embedding in paraffin, especially aft...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(03)00335-4

    authors: Tanaka R,Saito T,Ashihara K,Nishimura M,Mizumoto H,Kudo R

    更新日期:2003-08-01 00:00:00

  • Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.

    abstract:OBJECTIVE:Therapy related acute myeloid leukemia (t-AML) is a potential late complication of cytotoxic therapy, and it is of particular concern in the treatment of patients with epithelial ovarian carcinoma (EOC) exposed to multiple courses of chemotherapy during the course of their disease. This study examines the inc...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.07.097

    authors: Vay A,Kumar S,Seward S,Semaan A,Schiffer CA,Munkarah AR,Morris RT

    更新日期:2011-12-01 00:00:00

  • Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study).

    abstract::By serendipity we have had the opportunity to evaluate cis-platin-based chemotherapy in ovarian tumors of low malignant potential (LMP). Optimal (less than 1 cm residual disease) FIGO stage III ovarian carcinomas were randomly assigned to treatment with cisplatin plus cyclophosphamide with or without doxorubicin on a ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0090-8258(91)90314-u

    authors: Sutton GP,Bundy BN,Omura GA,Yordan EL,Beecham JB,Bonfiglio T

    更新日期:1991-06-01 00:00:00

  • First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.

    abstract::Current first-line management for advanced ovarian cancer consists of cytoreductive surgery followed by chemotherapy, usually with a platinum/taxane combination. Although this approach has been shown to achieve overall response rates of 70-80% in clinical trials, the majority of patients relapse. A number of different...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0090-8258(03)00472-4

    authors: Stuart GC

    更新日期:2003-09-01 00:00:00

  • Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus.

    abstract:OBJECTIVE:Many investigators have studied the expression of G1 phase regulatory protein in uterine cervical cancer. However, it is unclear which step of the genetic expression participates in cyclin D1 expression and what its prognostic meaning is. The aims of this study were to evaluate the regulatory level of cyclin ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2001.6196

    authors: Bae DS,Cho SB,Kim YJ,Whang JD,Song SY,Park CS,Kim DS,Lee JH

    更新日期:2001-06-01 00:00:00

  • Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.

    abstract:OBJECTIVES:Preclinical evaluation of the anti-neoplastic activity of an insulin-like growth factor I receptor (IGF-IR) kinase inhibitor in ovarian cancer. METHODS:The OVCAR-3 and OVCAR-4 cell lines were investigated under serum-free tissue culture conditions. IGF-I and IGF-II production were evaluated by standard ELIS...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.09.048

    authors: Gotlieb WH,Bruchim I,Gu J,Shi Y,Camirand A,Blouin MJ,Zhao Y,Pollak MN

    更新日期:2006-02-01 00:00:00